Liraglutide
- TRADE NAMES: Saxenda (Novo Nordisk); Victoza (Novo Nordisk); Xultophy (Novo Nordisk)
- INDICATIONS: To improve glycemic control in adults with Type II diabetes mellitus (Victoza); adjunct to diet and exercise for chronic weight management (Saxenda)
- CLASS: Glucagon-like peptide-1 (GLP-1) receptor agonist
- HALF-LIFE: 13 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acetaminophen, Atorvastatin, Digoxin, Griseofulvin, Lisinopril, Warfarin
PREGNANCY CATEGORY: C
Contra-indicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome Type 2.
Xultophy is liraglutide and insulin degludec.
RISK OF THYROID C-CELL TUMORS
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
GENITOURINARY
HEMATOLOGIC
LOCAL
NEUROMUSCULAR/SKELETAL
RENAL
RESPIRATORY
OTHER
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of the cardiovascular safety of liraglutide in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 01/19/2019
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
